Skip to main content
SpringerLink
Log in

C1 inhibitor: molecular and clinical aspects

  • Original Article
  • Published:
Springer Seminars in Immunopathology Aims and scope Submit manuscript

Abstract

C1 inhibitor (C1-INH) is a serine protease inhibitor (serpins) that inactivates several different proteases in the complement, contact, coagulation, and fibrinolytic systems. By its C-terminal part (serpin domain), characterized by three β-sheets and an exposed mobile reactive loop, C1-INH binds, and blocks the activity of its target proteases. The N-terminal end (nonserpin domain) confers to C1-INH the capacity to bind lipopolysaccharides and E-selectin. Owing to this moiety, C1-INH intervenes in regulation of the inflammatory reaction. The heterozygous deficiency of C1-INH results in hereditary angioedema (HAE). The clinical picture of HAE is characterized by bouts of local increase in vascular permeability. Depending on the affected site, patients suffer from disfiguring subcutaneous edema, abdominal pain, vomiting and/or diarrhoea for edema of the gastrointestinal mucosa, dysphagia, and dysphonia up to asphyxia for edema of the pharynx and larynx. Apart from its genetic deficiency, there are several pathological conditions such as ischemia–reperfusion, septic shock, capillary leak syndrome, and pancreatitis, in which C1-INH has been reported to either play a pathogenic role or be a potential therapeutic tool. These potential applications were identified long ago, but controlled studies have not been performed to confirm pilot experiences. Recombinant C1-INH, produced in transgenic animals, has recently been produced for treatment of HAE, and clinical trials are in progress. We can expect that the introduction of this new product, along with the existing plasma derivative, will renew interest in exploiting C1-INH as a therapeutic agent.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Pensky J, Levy LR, Lepow IH (1961) Partial purification of a serum inhibitor of C1 esterase. J Biol Chem 236:1674–1679

    PubMed  CAS  Google Scholar 

  2. Ratnoff OD, Pensky J, Donaldson VH, Amir J (1972) The inhibitory properties of plasma against activated plasma thromboplastin antecedent (factor XIa) in hereditary angioneurotic edema. J Lab Clin Med 80:803–809

    PubMed  CAS  Google Scholar 

  3. Harpel PC, Cooper NR (1975) Studies on human plasma C1 inactivator–enzyme interactions. I. Mechanisms of interaction with C1s, plasmin, and trypsin. J Clin Invest 55:593–604

    PubMed  CAS  Google Scholar 

  4. Sim RB, Arlaud GJ, Colomb MG (1979) C1 inhibitor-dependent dissociation of human complement component C1 bound to immune complexes. Biochem J 179:449–457

    PubMed  CAS  Google Scholar 

  5. Ziccardi RJ (1981) Activation of the early components of the classical complement pathway under physiologic conditions. J Immunol 126:1769–1773

    PubMed  CAS  Google Scholar 

  6. Schapira M, Scott CF, Colman RW (1982) Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma. J Clin Invest 69:462–468

    PubMed  CAS  Google Scholar 

  7. van der Graaf F, Koedam JA, Bouma BN (1983) Inactivation of kallikrein in human plasma. J Clin Invest 71:149–158

    PubMed  Google Scholar 

  8. de Agostini A, Lijnen HR, Pixley RA, Colman RW, Schapira M (1984) Inactivation of factor XII active fragment in normal plasma. Predominant role of C-1-inhibitor. J Clin Invest 73:1542–1549

    PubMed  Google Scholar 

  9. Harpel PC, Lewin MF, Kaplan AP (1985) Distribution of plasma kallikrein between C-1 inactivator and alpha 2-macroglobulin in plasma utilizing a new assay for alpha 2-macroglobulin–kallikrein complexes. J Biol Chem 260:4257–4263

    PubMed  CAS  Google Scholar 

  10. Pixley RA, Schapira M, Colman RW (1985) The regulation of human factor XIIa by plasma proteinase inhibitors. J Biol Chem 260:1723–1729

    PubMed  CAS  Google Scholar 

  11. Booth NA, Walker E, Maughan R, Bennett B (1987) Plasminogen activator in normal subjects after exercise and venous occlusion: t-PA circulates as complexes with C1-inhibitor and PAI-1. Blood 69:1600–1604

    PubMed  CAS  Google Scholar 

  12. Matsushita M, Thiel S, Jensenius JC, Terai I, Fujita T (2000) Proteolytic activities of two types of mannose-binding lectin-associated serine protease. J Immunol 165:2637–2642

    PubMed  CAS  Google Scholar 

  13. Jiang H, Wagner E, Zhang H, Frank MM (2001) Complement 1 inhibitor is a regulator of the alternative complement pathway. J Exp Med 194:1609–1616

    Article  PubMed  CAS  Google Scholar 

  14. Cugno M, Bos I, Lubbers Y, Hack CE, Agostoni A (2001) In vitro interaction of C1-inhibitor with thrombin. Blood Coagul Fibrinolysis 12:253–260

    Article  PubMed  CAS  Google Scholar 

  15. Patston PA, Gettins P, Beechem J, Schapira M (1991) Mechanism of serpin action: evidence that C1 inhibitor functions as a suicide substrate. Biochemistry 30:8876–8882

    Article  PubMed  CAS  Google Scholar 

  16. Lomas DA, Belorgey D, Mallya M, Miranda E, Kinghorn KJ, Sharp LK et al (2005) Molecular mousetraps and the serpinopathies(1). Biochem Soc Trans 33:321–330

    Article  PubMed  CAS  Google Scholar 

  17. Coutinho M, Aulak KS, Davis AE III (1994) Functional analysis of the serpin domain of C1 inhibitor. J Immunol 153:3648–3654

    PubMed  CAS  Google Scholar 

  18. Bock SC, Skriver K, Nielsen E, Thogersen HC, Wiman B, Donaldson VH et al (1986) Human C1 inhibitor: primary structure, cDNA cloning, and chromosomal localization. Biochemistry 25:4292–4301

    Article  PubMed  CAS  Google Scholar 

  19. Bos IG, Lubbers YT, Roem D, Abrahams JP, Hack CE, Eldering E (2003) The functional integrity of the serpin domain of C1-inhibitor depends on the unique N-terminal domain, as revealed by a pathological mutant. J Biol Chem 278:29463–29470

    Article  PubMed  CAS  Google Scholar 

  20. Liu D, Cai S, Gu X, Scafidi J, Wu X, Davis AE III (2003) C1 inhibitor prevents endotoxin shock via a direct interaction with lipopolysaccharide. J Immunol 171:2594–2601

    PubMed  CAS  Google Scholar 

  21. Liu D, Zhang D, Scafidi J, Wu X, Cramer CC, Davis AE III (2005) C1 inhibitor prevents Gram-negative bacterial lipopolysaccharide-induced vascular permeability. Blood 105:2350–2355

    Article  PubMed  CAS  Google Scholar 

  22. Vestweber D, Blanks JE (1999) Mechanisms that regulate the function of the selectins and their ligands. Physiol Rev 79:181–213

    PubMed  CAS  Google Scholar 

  23. Cai S, Davis AE III (2003) Complement regulatory protein C1 inhibitor binds to selectins and interferes with endothelial-leukocyte adhesion. J Immunol 171:4786–4791

    PubMed  CAS  Google Scholar 

  24. Cai S, Dole VS, Bergmeier W, Scafidi J, Feng H, Wagner DD et al (2005) A direct role for C1 inhibitor in regulation of leukocyte adhesion. J Immunol 174:6462–6466

    PubMed  CAS  Google Scholar 

  25. Lomas DA, Carrell RW (2002) Serpinopathies and the conformational dementias. Nat Rev Genet 3:759–768

    Article  PubMed  CAS  Google Scholar 

  26. Carrell RW, Lomas DA (1997) Conformational disease. Lancet 350:134–138

    Article  PubMed  CAS  Google Scholar 

  27. Lomas DA, Evans DL, Finch JT, Carrell RW (1992) The mechanism of Z alpha 1-antitrypsin accumulation in the liver. Nature 357:605–607

    Article  PubMed  CAS  Google Scholar 

  28. Carrell RW, Whisstock J, Lomas DA (1994) Conformational changes in serpins and the mechanism of alpha 1-antitrypsin deficiency [published erratum appears in Am J Respir Crit Care Med 1995 Mar;151(3 Pt 1):926]. Am J Respir Crit Care Med 150:S171–S175

    PubMed  CAS  Google Scholar 

  29. Owen MC, Brennan SO, Lewis JH, Carrell RW (1983) Mutation of antitrypsin to antithrombin. Alpha 1-antitrypsin Pittsburgh (358 Met leads to Arg), a fatal bleeding disorder. N Engl J Med 309:694–698

    PubMed  CAS  Google Scholar 

  30. Peterson FC, Gettins PG (2001) Insight into the mechanism of serpin-proteinase inhibition from 2D [1H–15N] NMR studies of the 69 kDa alpha 1-proteinase inhibitor Pittsburgh–trypsin covalent complex. Biochemistry 40:6284–6292

    Article  PubMed  CAS  Google Scholar 

  31. Millar DS, Wacey AI, Ribando J, Melissari E, Laursen B, Woods P et al (1994) Three novel missense mutations in the antithrombin III (AT3) gene causing recurrent venous thrombosis. Hum Genet 94:509–512

    Article  PubMed  CAS  Google Scholar 

  32. Lomas DA, Lourbakos A, Cumming SA, Belorgey D (2002) Hypersensitive mousetraps, alpha1-antitrypsin deficiency and dementia. Biochem Soc Trans 30:89–92

    Article  PubMed  CAS  Google Scholar 

  33. Donaldson VH, Evans RR (1963) A Biochemical abnormality in hereditary angioneurotic edema: absence of serum inhibitor of C′ 1-esterase. Am J Sci 31:37–44

    Google Scholar 

  34. Davis AE III, Whitehead AS, Harrison RA, Dauphinais A, Bruns GA, Cicardi M et al (1986) Human inhibitor of the first component of complement, C1: characterization of cDNA clones and localization of the gene to chromosome 11. Proc Natl Acad Sci U S A 83:3161–3165

    PubMed  CAS  Google Scholar 

  35. Tosi M, Duponchel C, Bourgarel P, Colomb M, Meo T (1986) Molecular cloning of human C1 inhibitor: sequence homologies with alpha 1-antitrypsin and other members of the serpins superfamily. Gene 42:265–272

    Article  PubMed  CAS  Google Scholar 

  36. Kalmar L, Hegedus T, Farkas H, Nagy M, Tordai A (2005) HAEdb: a novel interactive, locus-specific mutation database for the C1 inhibitor gene. Hum Mutat 25:1–5

    Article  PubMed  CAS  Google Scholar 

  37. Crowder JR, Crowder TR (1917) Five generations of angioneurotic edema. Arch Inter Med 20:840–852

    Google Scholar 

  38. Cicardi M, Igarashi T, Kim MS, Frangi D, Agostoni A, Davis AE III (1987) Restriction fragment length polymorphism of the C1 inhibitor gene in hereditary angioneurotic edema. J Clin Invest 80:1640–1643

    PubMed  CAS  Google Scholar 

  39. Stoppa-Lyonnet D, Tosi M, Laurent J, Sobel A, Lagrue G, Meo T (1987) Altered C1 inhibitor genes in type I hereditary angioedema. N Engl J Med 317:1–6

    PubMed  CAS  Google Scholar 

  40. Badano JL, Katsanis N (2002) Beyond Mendel: an evolving view of human genetic disease transmission. Nat Rev Genet 3:779–789

    Article  PubMed  CAS  Google Scholar 

  41. Agostoni A, Aygoren-Pursun E, Binkley KE, Blanch A, Bork K, Bouillet L et al (2004) Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol 114:S51–S131

    Article  PubMed  Google Scholar 

  42. Klemperer MR, Donaldson VH, Rosen FS (1968) Effect of C′1 esterase on vascular permeability in man: studies in normal and complement-deficient individuals and in patients with hereditary angioneurotic edema. J Clin Invest 47:604–611

    PubMed  CAS  Google Scholar 

  43. Donaldson VH, Ratnoff OD, Dias Da Silva W, Rosen FS (1969) Permeability-increasing activity in hereditary angioneurotic edema plasma. II. Mechanism of formation and partial characterization. J Clin Invest 48:642–653

    PubMed  CAS  Google Scholar 

  44. Donaldson VH, Rosen FS, Bing DH (1977) Role of the second component of complement (C2) and plasmin in kinin release in hereditary angioneurotic edema (H.A.N.E.) plasma. Trans Assoc Am Physicians 90:174–183

    PubMed  CAS  Google Scholar 

  45. Schapira M, Silver LD, Scott CF, Schmaier AH, Prograis LJ Jr, Curd JG et al (1983) Prekallikrein activation and high-molecular-weight kininogen consumption in hereditary angioedema. N Engl J Med 308:1050–1053

    PubMed  CAS  Google Scholar 

  46. Curd JG, Prograis LJ Jr, Cochrane CG (1980) Detection of active kallikrein in induced blister fluids of hereditary angioedema patients. J Exp Med 152:742–747

    Article  PubMed  CAS  Google Scholar 

  47. Fields T, Ghebrehiwet B, Kaplan AP (1983) Kinin formation in hereditary angioedema plasma: evidence against kinin derivation from C2 and in support of “spontaneous” formation of bradykinin. J Allergy Clin Immunol 72:54–60

    Article  PubMed  CAS  Google Scholar 

  48. Agostoni A, Aygoren-Pursun E, Binkley KE, Blanch A, Bork K, Bouillet L et al (2004) Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol 114:S51–S131

    Article  PubMed  Google Scholar 

  49. Davis AE (2003) The pathogenesis of hereditary angioedema. Transfus Apher Sci 29:195–203

    Article  PubMed  Google Scholar 

  50. Davis AE III (2005) The pathophysiology of hereditary angioedema. Clin Immunol 114:3–9

    Article  PubMed  CAS  Google Scholar 

  51. Shoemaker LR, Schurman SJ, Donaldson VH, Davis AE III (1994) Hereditary angioneurotic oedema: characterization of plasma kinin and vascular permeability-enhancing activities. Clin Exp Immunol 95:22–28

    PubMed  CAS  Google Scholar 

  52. Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A (1998) Plasma bradykinin in angio-oedema. Lancet 351:1693–1697

    Article  PubMed  CAS  Google Scholar 

  53. Nussberger J, Cugno M, Cicardi M, Agostoni A (1999) Local bradykinin generation in hereditary angioedema. J Allergy Clin Immunol 104:1321–1322

    PubMed  CAS  Google Scholar 

  54. Zahedi R, Wisnieski J, Davis AE III (1997) Role of the P2 residue of complement 1 inhibitor (Ala443) in determination of target protease specificity: inhibition of complement and contact system proteases. J Immunol 159:983–988

    PubMed  CAS  Google Scholar 

  55. Han ED, MacFarlane RC, Mulligan AN, Scafidi J, Davis AE III (2002) Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest 109:1057–1063

    Article  PubMed  CAS  Google Scholar 

  56. Han Lee ED, Pappalardo E, Scafidi J, Davis AE III (2003) Approaches toward reversal of increased vascular permeability in C1 inhibitor deficient mice. Immunol Lett 89:155–160

    Article  PubMed  CAS  Google Scholar 

  57. Icatibant: HOE 140, JE 049, JE049. Drugs R D (2004) 5:343–348

  58. Williams A, Baird LG (2003) DX-88 and HAE: a developmental perspective. Transfus Apher Sci 29:255–258

    Article  PubMed  Google Scholar 

  59. Cicardi M, Morrison J, Baird L, Williams A (2005) Plasma kallikrein inhibition: a viable method of treating laryngeal edema secondary to hereditary angioedema (HAE). J Allergy Clin Immunol 115:S203

    Article  Google Scholar 

  60. Agostoni A, Cicardi M (1992) Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltimore) 71:206–215

    CAS  Google Scholar 

  61. Bork K, Ressel N (2003) Sudden upper airway obstruction in patients with hereditary angioedema. Transfus Apher Sci 29:235–238

    Article  PubMed  Google Scholar 

  62. Gompels MM, Lock RJ, Abinun M, Bethune CA, Davies G, Grattan C et al (2005) C1 inhibitor deficiency: consensus document. Clin Exp Immunol 139:379–394

    Article  PubMed  CAS  Google Scholar 

  63. Bowen T, Cicardi M, Farkas H, Bork K, Kreuz W, Zingale L et al (2004) Canadian 2003 international consensus algorithm for the diagnosis, therapy, and management of hereditary angioedema. J Allergy Clin Immunol 114:629–637

    Article  PubMed  Google Scholar 

  64. Cicardi M, Zingale L (2003) How do we treat patients with hereditary angioedema. Transfus Apher Sci 29:221–227

    Article  PubMed  Google Scholar 

  65. Nuijens J, Verdonk R, Van Doorn M, Burggraaf K, Cohen A, Choi G et al (2005) Clinical studies of recombinant human C1 inhibitor in subjects with hereditary angioedema. J Allergy Clin Immunol 115:S202

    Article  Google Scholar 

  66. Bork K, Frank J, Kreuz W, Dong L, Rosenkranz B, Knolle J. Novel approach to treatment of hereditary angioedema with Icatibant, a bradykinin receptor antagonist. IV C1 inhibitor deficiency workshop, Budapest 29 April–1 May 2005; Abstract Book:19

  67. Agostoni A, Bergamaschini L, Martignoni G, Cicardi M, Marasini B (1980) Treatment of acute attacks of hereditary angioedema with C1-inhibitor concentrate. Ann Allergy 44:299–301

    PubMed  CAS  Google Scholar 

  68. Gadek JE, Hosea SW, Gelfand JA, Santaella M, Wickerhauser M, Triantaphyllopoulos DC et al (1980) Replacement therapy in hereditary angioedema: successful treatment of acute episodes of angioedema with partly purified C1 inhibitor. N Engl J Med 302:542–546

    PubMed  CAS  Google Scholar 

  69. Waytes AT, Rosen FS, Frank MM (1996) Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N Engl J Med 334:1630–1634

    Article  PubMed  CAS  Google Scholar 

  70. Bork K, Barnstedt SE (2001) Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema. Arch Intern Med 161:714–718

    Article  PubMed  CAS  Google Scholar 

  71. Riedemann NC, Ward PA (2003) Complement in ischemia reperfusion injury. Am J Pathol 162:363–367

    PubMed  Google Scholar 

  72. Monsinjon T, Richard V, Fontaine M (2001) Complement and its implications in cardiac ischemia/reperfusion: strategies to inhibit complement. Fundam Clin Pharmacol 15:293–306

    Article  PubMed  CAS  Google Scholar 

  73. Arumugam TV, Shiels IA, Woodruff TM, Granger DN, Taylor SM (2004) The role of the complement system in ischemia–reperfusion injury. Shock 21:401–409

    Article  PubMed  CAS  Google Scholar 

  74. Inderbitzin D, Beldi G, Avital I, Vinci G, Candinas D (2004) Local and remote ischemia–reperfusion injury is mitigated in mice overexpressing human C1 inhibitor. Eur Surg Res 36:142–147

    Article  PubMed  CAS  Google Scholar 

  75. Toomayan GA, Chen LE, Jiang HX, Qi WN, Seaber AV, Frank MM et al (2003) C1-esterase inhibitor and a novel peptide inhibitor improve contractile function in reperfused skeletal muscle. Microsurgery 23:561–567

    Article  PubMed  Google Scholar 

  76. Nielsen EW, Mollnes TE, Harlan JM, Winn RK (2002) C1-inhibitor reduces the ischaemia–reperfusion injury of skeletal muscles in mice after aortic cross-clamping. Scand J Immunol 56:588–592

    Article  PubMed  CAS  Google Scholar 

  77. Buerke M, Murohara T, Lefer AM (1995) Cardioprotective effects of a C1 esterase inhibitor in myocardial ischemia and reperfusion [see comments]. Circulation 91:393–402

    PubMed  CAS  Google Scholar 

  78. Horstick G, Heimann A, Gotze O, Hafner G, Berg O, Boehmer P et al (1997) Intracoronary application of C1 esterase inhibitor improves cardiac function and reduces myocardial necrosis in an experimental model of ischemia and reperfusion. Circulation 95:701–708

    PubMed  CAS  Google Scholar 

  79. Buerke M, Prufer D, Dahm M, Oelert H, Meyer J, Darius H (1998) Blocking of classical complement pathway inhibits endothelial adhesion molecule expression and preserves ischemic myocardium from reperfusion injury. J Pharmacol Exp Ther 286:429–438

    PubMed  CAS  Google Scholar 

  80. Horstick G, Berg O, Heimann A, Gotze O, Loos M, Hafner G et al (2001) Application of C1-esterase inhibitor during reperfusion of ischemic myocardium: dose-related beneficial versus detrimental effects. Circulation 104:3125–3131

    PubMed  CAS  Google Scholar 

  81. Bauernschmitt R, Bohrer H, Hagl S (1998) Rescue therapy with C1-esterase inhibitor concentrate after emergency coronary surgery for failed PTCA. Intensive Care Med 24:635–638

    Article  PubMed  CAS  Google Scholar 

  82. de Zwaan C, Kleine AH, Diris JH, Glatz JF, Wellens HJ, Strengers PF et al (2002) Continuous 48-h C1-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction. Eur Heart J 23:1670–1677

    PubMed  Google Scholar 

  83. De Simoni MG, Rossi E, Storini C, Pizzimenti S, Echart C, Bergamaschini L (2004) The powerful neuroprotective action of C1-inhibitor on brain ischemia–reperfusion injury does not require C1q. Am J Pathol 164:1857–1863

    PubMed  Google Scholar 

  84. De Simoni MG, Storini C, Barba M, Catapano L, Arabia AM, Rossi E et al (2003) Neuroprotection by complement (C1) inhibitor in mouse transient brain ischemia. J Cereb Blood Flow Metab 23:232–239

    Article  PubMed  Google Scholar 

  85. Storini C, Rossi E, Marrella V, Distaso M, Veerhuis R, Vergani C et al (2005) C1-inhibitor protects against brain ischemia–reperfusion injury via inhibition of cell recruitment and inflammation. Neurobiol Dis 19:10–17

    Article  PubMed  CAS  Google Scholar 

  86. Heimann A, Takeshima T, Horstick G, Kempski O (1999) C1-esterase inhibitor reduces infarct volume after cortical vein occlusion. Brain Res 838:210–213

    Article  PubMed  CAS  Google Scholar 

  87. Akita N, Nakase H, Kaido T, Kanemoto Y, Sakaki T (2003) Protective effect of C1 esterase inhibitor on reperfusion injury in the rat middle cerebral artery occlusion model. Neurosurgery 52:395–400 (discussion-1)

    Article  PubMed  Google Scholar 

  88. Heikkinen J, Koskenkari J, Kaakinen T, Dahlbacka S, Kiviluoma K, Salomaki T et al (2004) Apotransferrin, C1-esterase inhibitor, and alpha 1-acid glycoprotein for cerebral protection during experimental hypothermic circulatory arrest. Scand Cardiovasc J 38:178–186

    PubMed  CAS  Google Scholar 

  89. Lehmann TG, Heger M, Munch S, Kirschfink M, Klar E (2000) In vivo microscopy reveals that complement inhibition by C1-esterase inhibitor reduces ischemia/reperfusion injury in the liver. Transpl Int 13:S547–S550

    Article  PubMed  Google Scholar 

  90. Scherer M, Demertzis S, Langer F, Moritz A, Schafers HJ (2002) C1-esterase inhibitor reduces reperfusion injury after lung transplantation. Ann Thorac Surg 73:233–238 (discussion 8–9)

    Article  PubMed  Google Scholar 

  91. Bergamaschini L, Gatti S, Caccamo L, Prato P, Latham L, Trezza P et al (2001) C1 inhibitor potentiates the protective effect of organ preservation solution on endothelial cells during cold storage. Transplant Proc 33:939–941

    Article  PubMed  CAS  Google Scholar 

  92. Bergamaschini L, Gobbo G, Gatti S, Caccamo L, Prato P, Maggioni M et al (2001) Endothelial targeting with C1-inhibitor reduces complement activation in vitro and during ex vivo reperfusion of pig liver. Clin Exp Immunol 126:412–420

    Article  PubMed  CAS  Google Scholar 

  93. Kalter ES, Daha MR, ten Cate JW, Verhoef J, Bouma BN (1985) Activation and inhibition of Hageman factor-dependent pathways and the complement system in uncomplicated bacteremia or bacterial shock. J Infect Dis 151:1019–1027

    PubMed  CAS  Google Scholar 

  94. Nuijens JH, Huijbregts CC, Eerenberg-Belmer AJ, Abbink JJ, Strack van Schijndel RJ, Felt-Bersma RJ et al (1988) Quantification of plasma factor XIIa-Cl(−)-inhibitor and kallikrein-Cl(−)-inhibitor complexes in sepsis. Blood 72:1841–1848

    PubMed  CAS  Google Scholar 

  95. de Boer JP, Creasey AA, Chang A, Roem D, Eerenberg AJ, Hack CE et al (1993) Activation of the complement system in baboons challenged with live Escherichia coli: correlation with mortality and evidence for a biphasic activation pattern. Infect Immun 61:4293–4301

    PubMed  Google Scholar 

  96. Jansen PM, Eisele B, de Jong IW, Chang A, Delvos U, Taylor FB Jr et al (1992) Effect of C1 inhibitor on inflammatory and physiologic response patterns in primates suffering from lethal septic shock. J Immunol 160:475–484

    Google Scholar 

  97. Jansen PM, Pixley RA, Brouwer M, de Jong IW, Chang AC, Hack CE et al (1996) Inhibition of factor XII in septic baboons attenuates the activation of complement and fibrinolytic systems and reduces the release of interleukin-6 and neutrophil elastase. Blood 87:2337–2344

    PubMed  CAS  Google Scholar 

  98. Fischer MB, Prodeus AP, Nicholson-Weller A, Ma M, Murrow J, Reid RR et al (1997) Increased susceptibility to endotoxin shock in complement C3- and C4-deficient mice is corrected by C1 inhibitor replacement. J Immunol 159:976–982

    PubMed  CAS  Google Scholar 

  99. Hack CE, Voerman HJ, Eisele B, Keinecke HO, Nuijens JH, Eerenberg AJ et al (1992) C1-esterase inhibitor substitution in sepsis. Lancet 339:378

    Article  PubMed  CAS  Google Scholar 

  100. Marx G, Nashan B, Cobas Meyer M, Vangerow B, Schlitt HJ, Ziesing S et al (1999) Septic shock after liver transplantation for Caroli’s disease: clinical improvement after treatment with C1-esterase inhibitor. Intensive Care Med 25:1017–1020

    Article  PubMed  CAS  Google Scholar 

  101. Caliezi C, Zeerleder S, Redondo M, Regli B, Rothen HU, Zurcher-Zenklusen R et al (2002) C1-inhibitor in patients with severe sepsis and septic shock: beneficial effect on renal dysfunction. Crit Care Med 30:1722–1728

    Article  PubMed  CAS  Google Scholar 

  102. Kruse P, Hage E, Lasson A (1999) Proteases and protease inhibitors in taurocholate-induced acute pancreatitis in rats. Int J Pancreatol 25:113–121

    PubMed  CAS  Google Scholar 

  103. Yamaguchi H, Weidenbach H, Luhrs H, Lerch MM, Dickneite G, Adler G (1997) Combined treatment with C1 esterase inhibitor and antithrombin III improves survival in severe acute experimental pancreatitis. Gut 40:531–535

    PubMed  CAS  Google Scholar 

  104. Niederau C, Brinsa R, Niederau M, Luthen R, Strohmeyer G, Ferrell LD (1995) Effects of C1-esterase inhibitor in three models of acute pancreatitis. Int J Pancreatol 17:189–196

    PubMed  CAS  Google Scholar 

  105. Vesentini S, Benetti L, Bassi C, Bonora A, Campedelli A, Zamboni G et al (1993) Effects of choline-esterase inhibitor in experimental acute pancreatitis in rats. Preliminary results. Int J Pancreatol 13:217–220

    PubMed  CAS  Google Scholar 

  106. Ruud TE, Aasen AO, Pillgram-Larsen J, Stadaas JO (1986) Effects on peritoneal proteolysis and hemodynamics of prophylactic infusion with C1 inhibitor in experimental acute pancreatitis. Scand J Gastroenterol 21:1018–1024

    PubMed  CAS  Google Scholar 

  107. Schneider DT, Nurnberger W, Stannigel H, Bonig H, Gobel U (1999) Adjuvant treatment of severe acute pancreatitis with C1 esterase inhibitor concentrate after haematopoietic stem cell transplantation. Gut 45:733–736

    PubMed  CAS  Google Scholar 

  108. Testoni PA, Cicardi M, Bergamaschini L, Guzzoni S, Cugno M, Buizza M et al (1995) Infusion of C1-inhibitor plasma concentrate prevents hyperamylasemia induced by endoscopic sphincterotomy. Gastrointest Endosc 42:301–305

    PubMed  CAS  Google Scholar 

  109. Mikkonen R, Aronen HJ, Kivisaari L, Piilonen A, Syrjala M (1997) Plasma levels of prekallikrein, alpha-2-macroglobulin and C1-esterase inhibitor in patients with urticarial reaction to contrast media. Acta Radiol 38:466–473

    PubMed  CAS  Google Scholar 

  110. Hoffmeister HM, Heller W (1996) Radiographic contrast media and the coagulation and complement systems [see comments]. Invest Radiol 31:591–595

    Article  PubMed  CAS  Google Scholar 

  111. Aronen HJ, Kivisaari L, Torstila I, Paavonen T, Meri S, Karonen SL et al (1992) Level of plasma prekallikrein and its inhibitors in reactors and nonreactors during intravenous enhancement with contrast media. Acta Radiol 33:374–378

    PubMed  CAS  Google Scholar 

  112. Hagan JJ, Yost FJ, Nickoloff EL (1987) Prekallikrein activation, C1 esterase inhibitor, and factor XII as predictors of adverse reaction to contrast media. A prospective study. Invest Radiol 22:490–494

    PubMed  CAS  Google Scholar 

  113. Mathews KP, Pan PM, Amendola MA, Lewis FH (1986) Plasma protease inhibitor and anaphylatoxin inactivator levels in chronic urticaria/angioedema and in patients experiencing anaphylactoid reactions to radiographic contrast media. Int Arch Allergy Appl Immunol 79:220–223

    PubMed  CAS  Google Scholar 

  114. Johansen HT, Hoem NO, Veggeland T, Briseid K (1986) Assay of kallikrein inhibitors and levels of acetone-activated kallikrein in plasma specimens from reactors to dextran or to contrast media. Int J Tissue React 8:185–192

    PubMed  CAS  Google Scholar 

  115. Lasser EC, Lang JH, Lyon SG, Hamblin AE (1979) Complement and contrast material reactors. J Allergy Clin Immunol 64:105–112

    Article  PubMed  CAS  Google Scholar 

  116. Gardinali M, Cicardi M, Frangi D, Franzinelli M, Gattoni F, Uslenghi C et al (1986) In vivo study of the complement system during infusion of radiographic contrast media. J Allergy Clin Immunol 77:690–692

    Article  PubMed  CAS  Google Scholar 

  117. Clarkson B, Thompson D, Horwith M, Luckey EH (1960) Cyclical edema and shock due to increased capillary permeability. Am J Med 29:193–216

    Article  PubMed  CAS  Google Scholar 

  118. Kirschfink M, Nurnberger W (1999) C1 inhibitor in anti-inflammatory therapy: from animal experiment to clinical application. Mol Immunol 36:225–232

    Article  PubMed  CAS  Google Scholar 

  119. Hazelzet JA, de Groot R, van Mierlo G, Joosten KF, van der Voort E, Eerenberg A et al (1998) Complement activation in relation to capillary leakage in children with septic shock and purpura. Infect Immun 66:5350–5356

    PubMed  CAS  Google Scholar 

  120. Stiller B, Sonntag J, Dahnert I, Alexi-Meskishvili V, Hetzer R, Fischer T et al (2001) Capillary leak syndrome in children who undergo cardiopulmonary bypass: clinical outcome in comparison with complement activation and C1 inhibitor. Intensive Care Med 27:193–200

    Article  PubMed  CAS  Google Scholar 

  121. Radke A, Mottaghy K, Goldmann C, Khorram-Sefat R, Kovacs B, Janssen A et al (2000) C1 inhibitor prevents capillary leakage after thermal trauma. Crit Care Med 28:3224–3232

    Article  PubMed  CAS  Google Scholar 

  122. Seghaye MC, Grabitz RG, Duchateau J, Busse S, Dabritz S, Koch D et al (1996) Inflammatory reaction and capillary leak syndrome related to cardiopulmonary bypass in neonates undergoing cardiac operations. J Thorac Cardiovasc Surg 112:687–697

    PubMed  CAS  Google Scholar 

  123. Heller A, Kunz M, Samakas A, Haase M, Kirschfink M, Koch T (2000) The complement regulators C1 inhibitor and soluble complement receptor 1 attenuate acute lung injury in rabbits. Shock 13:285–290

    PubMed  CAS  Google Scholar 

  124. Schmidt S, Hertfelder HJ, von Spiegel T, Hering R, Harzheim M, Lassmann H et al (1999) Lethal capillary leak syndrome after a single administration of interferon beta-1b. Neurology 53:220–222

    PubMed  CAS  Google Scholar 

  125. Nurnberger W, Heying R, Burdach S, Gobel U (1997) C1 esterase inhibitor concentrate for capillary leakage syndrome following bone marrow transplantation. Ann Hematol 75:95–101

    Article  PubMed  CAS  Google Scholar 

  126. Salat C, Holler E, Schleuning M, Eisele B, Reinhardt B, Kolb H et al (1995) Levels of the terminal complement complex, C3a-desArg and C1-inhibitor in adult patients with capillary leak syndrome following bone marrow transplantation. Ann Hematol 71:271–274

    PubMed  CAS  Google Scholar 

  127. Hack CE, Ogilvie AC, Eisele B, Jansen PM, Wagstaff J, Thijs LG (1994) Initial studies on the administration of C1-esterase inhibitor to patients with septic shock or with a vascular leak syndrome induced by interleukin-2 therapy. Prog Clin Biol Res 388:335–357

    PubMed  CAS  Google Scholar 

  128. Nurnberger W, Michelmann I, Petrik K, Holthausen S, Willers R, Lauermann G et al (1993) Activity of C1 esterase inhibitor in patients with vascular leak syndrome after bone marrow transplantation. Ann Hematol 67:17–21

    Article  PubMed  CAS  Google Scholar 

  129. Hack CE, Ogilvie AC, Eisele B, Eerenberg AJ, Wagstaff J, Thijs LG (1993) C1-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2. Intensive Care Med 19:S19–S28

    Article  PubMed  Google Scholar 

  130. Nurnberger W, Gobel U, Stannigel H, Eisele B, Janssen A, Delvos U (1992) C1-inhibitor concentrate for sepsis-related capillary leak syndrome. Lancet 339:990

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, San Giuseppe Hospital, University of Milan, Milan, Italy

    Marco Cicardi, Lorenza Zingale, Andrea Zanichelli, Emanuela Pappalardo & Benedetta Cicardi

  2. Dipartimento di Medicina Interna, IRCCS Maggiore Hospital, University of Milan, Via Pace 9, 20122, Milan, Italy

    Marco Cicardi

Authors
  1. Marco Cicardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lorenza Zingale
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andrea Zanichelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Emanuela Pappalardo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Benedetta Cicardi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marco Cicardi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cicardi, M., Zingale, L., Zanichelli, A. et al. C1 inhibitor: molecular and clinical aspects. Springer Semin Immun 27, 286–298 (2005). https://doi.org/10.1007/s00281-005-0001-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00281-005-0001-4

Keywords

Search

Navigation